Cardiovascular Therapeutics / 2019 / Article / Tab 1

Research Article

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors

Table 1

Baseline characteristics.

CharacteristicsPatients (n = 66)

Age, years72 ± 10
Male sex (n, %)61 (92)
Race or ethnic group (n, %)
 White65 (98)
 Black1 (2)
Systolic blood pressure, mmHg121 ± 17
Diastolic blood pressure, mmHg72 ± 11
Ejection fraction, %30 ± 6
Heart rate, beats/min76 ± 18
Serum potassium, mmol/L4.4 ± 0.4
Serum creatinine, μmol/L107 ± 24
Creatinine clearance, ml/min76 ± 32
Body weight, kg93 ± 21
BMI, kg/m231 ± 10
NT-proBNP, ng/L (median, IQR)1612 (774-3515)
NYHA class (n, %)
 I2 (3)
 II19 (29)
 III40 (61)
 IV5 (7)
Medical history (n, %)
 Hypertension42 (64)
 Diabetes19 (29)
 Coronary artery disease37 (56)
 Atrial fibrillation35 (53)
Medications (n, %)
 ACE inhibitor37 (56)
 ARB29 (59)
 Beta-blocker63 (95)
 MRA47 (71)
 Diuretics42 (64)

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; IQR, Interquartile range; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.
All values were reported as mean ± standard deviation unless otherwise indicated.
All patients were prescribed ACE inhibitors or ARBs in doses equivalent to enalapril 20 mg daily.